After therapeutic period, Andro could remarkably reduce IL-6, IL-1β, TNF-α, VEGF, MMP-2 level in blood and IL-10, TGF-β, NF-κB level of tumor tissue with significantly statistical implications (p < 0.01). This evidence concerns the gene IL1B and neoplasm.